drugset / Trial / NCT02418624

Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer

NCT02418624

Phase 1 Completed 25 enrolled The Netherlands Cancer Institute
NaSingle-groupOpen-labelTreatment

Summary

A phase I trial to determine the recommended phase two dose of the combination of carboplatin and olaparib.

Timeline

Start
2015-05
Primary completion
2019-01
Completion
2019-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 3 unknown
Subject Carboplatin Small molecule 4 unknown
Subject Olaparib Small molecule 25 mg
Subject Olaparib Small molecule 50 mg
Subject Olaparib Small molecule 75 mg
Subject Olaparib Small molecule 100 mg
Subject Olaparib Small molecule 300 mg